Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost
South Africa
Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende-Zuma, Azwidhwi Takalani, Kubashni Woeber, Annie Bodenstein, Phumeza Jonas, Imke Engelbrecht, Waasila Jassat, Harry Moultrie, Debbie Bradshaw, Ishen Seocharan, Jackline Odhiambo, Kentse Khuto, Simone I. Richardson, Millicent A. Omondi, Rofhiwa Nesamari,
Created on
April 29, 2024
Last modified
April 29, 2024
Page views
24643
Download
2
Documentation in PDF
Metadata
DDI/XML
JSON
- Data files
- SHERPA_Safetydata
cd4_count_2 (cd4_count_2)
Data file: SHERPA_Safetydata
Overview
Valid:
2957
Invalid:
0
Type:
Discrete
Width:
29
Range:
-
Format:
character
Questions and instructions
Categories
| Value | Category | Cases | |
|---|---|---|---|
| +/- 400 | 1 |
0%
|
|
| +/-700 | 1 |
0%
|
|
| -1000 | 3 |
0.1%
|
|
| -1200 | 1 |
0%
|
|
| -500 | 2 |
0.1%
|
|
| -599 | 1 |
0%
|
|
| -600 | 1 |
0%
|
|
| -700 | 3 |
0.1%
|
|
| -900 | 2 |
0.1%
|
|
| 1000 | 16 |
0.5%
|
|
| 1000 approximately | 1 |
0%
|
|
| 1002 | 3 |
0.1%
|
|
| 1003 | 1 |
0%
|
|
| 1004 | 1 |
0%
|
|
| 1005 | 1 |
0%
|
|
| 100684 | 1 |
0%
|
|
| 1008 | 1 |
0%
|
|
| 1012 | 1 |
0%
|
|
| 1020 | 1 |
0%
|
|
| 1028 | 1 |
0%
|
|
| 1031 | 1 |
0%
|
|
| 1032 | 1 |
0%
|
|
| 1038 | 1 |
0%
|
|
| 1045 | 1 |
0%
|
|
| 1052 | 1 |
0%
|
|
| 1054 | 1 |
0%
|
|
| 1070 | 1 |
0%
|
|
| 1077 | 1 |
0%
|
|
| 1079 | 1 |
0%
|
|
| 1084 | 1 |
0%
|
|
| 1091 | 1 |
0%
|
|
| 1092 | 1 |
0%
|
|
| 1093 | 1 |
0%
|
|
| 1096 | 1 |
0%
|
|
| 1100 | 2 |
0.1%
|
|
| 1124 | 1 |
0%
|
|
| 1134 | 1 |
0%
|
|
| 1140 | 1 |
0%
|
|
| 1150 | 1 |
0%
|
|
| 1192 | 1 |
0%
|
|
| 1195 | 1 |
0%
|
|
| 1200 | 2 |
0.1%
|
|
| 1200 cells/mm3 | 1 |
0%
|
|
| 1229 | 1 |
0%
|
|
| 1234 | 1 |
0%
|
|
| 1268 | 1 |
0%
|
|
| 1299 | 1 |
0%
|
|
| 1300 | 3 |
0.1%
|
|
| 1350 | 1 |
0%
|
|
| 1356 | 1 |
0%
|
|
| 1361 | 1 |
0%
|
|
| 1390 | 1 |
0%
|
|
| 144 | 1 |
0%
|
|
| 1500 | 2 |
0.1%
|
|
| 15032022 with normal ranges | 1 |
0%
|
|
| 15062022 | 1 |
0%
|
|
| 1550 | 1 |
0%
|
|
| 1624 | 1 |
0%
|
|
| 170 | 1 |
0%
|
|
| 1705 cells/ml | 1 |
0%
|
|
| 2000 | 1 |
0%
|
|
| 2021-01-01 | 1 |
0%
|
|
| 250 | 1 |
0%
|
|
| 264 | 1 |
0%
|
|
| 267 Cells / UL ( 1.3.2019 ) | 1 |
0%
|
|
| 2700 | 1 |
0%
|
|
| 284 cells/ul | 1 |
0%
|
|
| 29 Feb 2022 | 1 |
0%
|
|
| 291 | 1 |
0%
|
|
| 298 | 1 |
0%
|
|
| 350 | 1 |
0%
|
|
| 354 | 1 |
0%
|
|
| 362 | 1 |
0%
|
|
| 380 | 2 |
0.1%
|
|
| 389 | 2 |
0.1%
|
|
| 391 | 1 |
0%
|
|
| 400 | 3 |
0.1%
|
|
| 401 | 1 |
0%
|
|
| 402 | 1 |
0%
|
|
| 413 March 2016 | 1 |
0%
|
|
| 420 | 1 |
0%
|
|
| 439 | 1 |
0%
|
|
| 442 | 1 |
0%
|
|
| 450 | 3 |
0.1%
|
|
| 459 | 1 |
0%
|
|
| 464 | 2 |
0.1%
|
|
| 470 | 2 |
0.1%
|
|
| 475 | 2 |
0.1%
|
|
| 480 | 1 |
0%
|
|
| 480 cells/uL | 1 |
0%
|
|
| 482 | 2 |
0.1%
|
|
| 483 | 1 |
0%
|
|
| 490 | 1 |
0%
|
|
| 495 | 1 |
0%
|
|
| 50 | 1 |
0%
|
|
| 500 | 10 |
0.3%
|
|
| 503 | 2 |
0.1%
|
|
| 512 | 1 |
0%
|
|
| 520 | 1 |
0%
|
|
| 521 | 1 |
0%
|
|
| 528 | 2 |
0.1%
|
|
| 530 | 2 |
0.1%
|
|
| 531 | 1 |
0%
|
|
| 534 | 1 |
0%
|
|
| 536 | 1 |
0%
|
|
| 540 | 2 |
0.1%
|
|
| 548 | 1 |
0%
|
|
| 550 | 2 |
0.1%
|
|
| 555 | 1 |
0%
|
|
| 556 | 1 |
0%
|
|
| 560 | 3 |
0.1%
|
|
| 564 | 2 |
0.1%
|
|
| 569 | 1 |
0%
|
|
| 572 | 1 |
0%
|
|
| 580 | 2 |
0.1%
|
|
| 582 | 1 |
0%
|
|
| 586 | 1 |
0%
|
|
| 594 | 1 |
0%
|
|
| 595 | 2 |
0.1%
|
|
| 600 | 8 |
0.3%
|
|
| 610 | 1 |
0%
|
|
| 621 | 1 |
0%
|
|
| 624 | 1 |
0%
|
|
| 635 | 1 |
0%
|
|
| 645 | 1 |
0%
|
|
| 650 | 2 |
0.1%
|
|
| 657 | 1 |
0%
|
|
| 661 Cells / U1 ( 11.12.2018 ) | 1 |
0%
|
|
| 668 | 1 |
0%
|
|
| 670 | 2 |
0.1%
|
|
| 673 | 2 |
0.1%
|
|
| 675 | 1 |
0%
|
|
| 68 | 1 |
0%
|
|
| 680 | 1 |
0%
|
|
| 682 | 1 |
0%
|
|
| 683 | 1 |
0%
|
|
| 684 | 1 |
0%
|
|
| 685 | 1 |
0%
|
|
| 687 | 1 |
0%
|
|
| 700 | 10 |
0.3%
|
|
| 716 | 1 |
0%
|
|
| 721 | 1 |
0%
|
|
| 723 | 2 |
0.1%
|
|
| 724 | 1 |
0%
|
|
| 725 | 1 |
0%
|
|
| 729 | 2 |
0.1%
|
|
| 730 | 1 |
0%
|
|
| 734 | 1 |
0%
|
|
| 735 | 1 |
0%
|
|
| 738 | 1 |
0%
|
|
| 740 | 2 |
0.1%
|
|
| 741 | 1 |
0%
|
|
| 745 | 1 |
0%
|
|
| 748 | 1 |
0%
|
|
| 749 | 1 |
0%
|
|
| 750 | 3 |
0.1%
|
|
| 7500 | 1 |
0%
|
|
| 751 | 1 |
0%
|
|
| 754 | 1 |
0%
|
|
| 764 | 1 |
0%
|
|
| 768 | 1 |
0%
|
|
| 770's | 1 |
0%
|
|
| 772 | 1 |
0%
|
|
| 78.2 | 1 |
0%
|
|
| 781 | 1 |
0%
|
|
| 782 | 1 |
0%
|
|
| 785 | 1 |
0%
|
|
| 787 | 2 |
0.1%
|
|
| 788 | 2 |
0.1%
|
|
| 789 | 2 |
0.1%
|
|
| 791 | 1 |
0%
|
|
| 800 | 11 |
0.4%
|
|
| 800 cells/ul | 1 |
0%
|
|
| 802 | 1 |
0%
|
|
| 805 | 1 |
0%
|
|
| 807 | 1 |
0%
|
|
| 818 | 1 |
0%
|
|
| 820 | 1 |
0%
|
|
| 824 | 1 |
0%
|
|
| 825 | 1 |
0%
|
|
| 834 | 1 |
0%
|
|
| 835 | 1 |
0%
|
|
| 836 | 1 |
0%
|
|
| 840 | 2 |
0.1%
|
|
| 843 | 1 |
0%
|
|
| 845 | 1 |
0%
|
|
| 846 | 1 |
0%
|
|
| 849 | 1 |
0%
|
|
| 850 | 2 |
0.1%
|
|
| 851 | 1 |
0%
|
|
| 860 | 2 |
0.1%
|
|
| 870 | 1 |
0%
|
|
| 874 | 2 |
0.1%
|
|
| 875 | 1 |
0%
|
|
| 876 | 2 |
0.1%
|
|
| 888 | 1 |
0%
|
|
| 890 | 2 |
0.1%
|
|
| 894 | 1 |
0%
|
|
| 894 copies | 1 |
0%
|
|
| 895 | 1 |
0%
|
|
| 899 | 1 |
0%
|
|
| 900 | 7 |
0.2%
|
|
| 902 | 1 |
0%
|
|
| 903 | 1 |
0%
|
|
| 906 | 1 |
0%
|
|
| 908 | 1 |
0%
|
|
| 909 | 1 |
0%
|
|
| 910 | 1 |
0%
|
|
| 920 | 1 |
0%
|
|
| 926 | 1 |
0%
|
|
| 930 | 1 |
0%
|
|
| 935 | 1 |
0%
|
|
| 936 | 1 |
0%
|
|
| 937 | 1 |
0%
|
|
| 946 | 1 |
0%
|
|
| 950 | 3 |
0.1%
|
|
| 978 | 2 |
0.1%
|
|
| 980 | 2 |
0.1%
|
|
| 981 cells/mm3 | 1 |
0%
|
|
| 984 | 2 |
0.1%
|
|
| 985 | 1 |
0%
|
|
| 986 | 1 |
0%
|
|
| 988 | 1 |
0%
|
|
| 990 | 2 |
0.1%
|
|
| 995 | 1 |
0%
|
|
| 996 | 2 |
0.1%
|
|
| 998 | 2 |
0.1%
|
|
| <500 | 3 |
0.1%
|
|
| >1000 | 2 |
0.1%
|
|
| >400 | 2 |
0.1%
|
|
| >500 | 7 |
0.2%
|
|
| >900 | 1 |
0%
|
|
| Awaiting Results | 1 |
0%
|
|
| BK | 2 |
0.1%
|
|
| Bloods were fine | 1 |
0%
|
|
| Controlled | 1 |
0%
|
|
| D/K | 10 |
0.3%
|
|
| DK | 2273 |
76.9%
|
|
| DKI | 1 |
0%
|
|
| DKJ | 1 |
0%
|
|
| DNK | 1 |
0%
|
|
| Dk | 45 |
1.5%
|
|
| Dolutegravir | 1 |
0%
|
|
| Don't Know | 1 |
0%
|
|
| Don't know | 2 |
0.1%
|
|
| Due for 28 Oct 2022 | 1 |
0%
|
|
| N/A | 29 |
1%
|
|
| NA | 1 |
0%
|
|
| NOT KNOWN | 1 |
0%
|
|
| Not Known | 1 |
0%
|
|
| Not avaialble | 1 |
0%
|
|
| Not available | 1 |
0%
|
|
| Not certain | 1 |
0%
|
|
| Not detected | 1 |
0%
|
|
| Not known | 9 |
0.3%
|
|
| Participant does not remember | 1 |
0%
|
|
| UK August 2021 | 1 |
0%
|
|
| UNDETECTABLE | 1 |
0%
|
|
| UNDETECTED | 1 |
0%
|
|
| UNK | 9 |
0.3%
|
|
| UNKNOWN | 14 |
0.5%
|
|
| UNKOWN | 3 |
0.1%
|
|
| Undetectable | 2 |
0.1%
|
|
| Unknown | 35 |
1.2%
|
|
| Unkown | 8 |
0.3%
|
|
| Within normal ranges | 1 |
0%
|
|
| dk | 90 |
3%
|
|
| dont know | 1 |
0%
|
|
| over 1000 | 1 |
0%
|
|
| participant dont remember | 5 |
0.2%
|
|
| un-Aug 2022 | 1 |
0%
|
|
| undetectable | 1 |
0%
|
|
| unk | 4 |
0.1%
|
|
| unknown | 22 |
0.7%
|
|
| unkown | 14 |
0.5%
|
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.